Quick Answer
Viridian Therapeutics, Inc.DE reported Research And Development Expense of $34.79 million for the year ending 2019.
- Viridian Therapeutics, Inc.DE showed an increase of +14.4% in Research And Development Expense from 2018 to 2019.
- This data is from Viridian Therapeutics, Inc.DE's annual report (Form 10-K), filed with the SEC on March 13, 2020.
- XBRL data for this metric is available from 2013 to 2019 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2013 to 2019), Viridian Therapeutics, Inc.DE's Research And Development Expense has grown by 15,364.0%.
- Historical annual values: Fiscal year 2019: $34.79 million | Fiscal year 2018: $30.42 million | Fiscal year 2017: $19.62 million | Fiscal year 2016: $13.69 million | Fiscal year 2015: $1.00 million | Fiscal year 2014: $347.0 thousand | Fiscal year 2013: $225.0 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: